玻璃体切除术联合玻璃体腔内注射康柏西普治疗增生性糖尿病视网膜病变患者的效果  

Effect of Vitrectomy Combined with Intravitreal Injection of Conbercept in the Treatment of Proliferative Diabetic Retinopathy

作　　者：覃雪 宋平 潘红莲 QIN Xue;SONG Ping;PAN Honglian(The Affiliated Eye Hospital of Nanjing Medical University,Nanjing 210000,China;不详)

机构地区：[1]南京医科大学眼科医院,江苏南京210000

出　　处：《中外医学研究》2024年第35期35-38,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探究玻璃体切除术联合玻璃体腔内注射康柏西普治疗增生性糖尿病视网膜病变患者的效果。方法:回顾性选取2022年10月—2023年10月南京医科大学眼科医院收治的76例增生性糖尿病视网膜病变患者。根据治疗方案的不同将其分为对照组和观察组,各38例。对照组给予玻璃体切除术,观察组给予玻璃体切除术联合玻璃体腔内注射康柏西普。比较两组恢复情况、血清因子、生活质量及安全性。结果:术后3个月,观察组最佳矫正视力(BCVA)、眼压、黄斑中心视网膜厚度(CRT)均低于对照组,差异有统计学意义(P<0.05)。术后3个月,观察组血管内皮生长因子(VEGF)、胎盘生长因子(PIGF)水平均低于对照组,差异有统计学意义(P<0.05)。术后3个月,观察组中文版低视力者生活质量量表(CLVQOL)评分高于对照组,差异有统计学意义(P<0.05)。观察组并发症发生率低于对照组,差异有统计学意义(P<0.05)。结论:玻璃体切除术前玻璃体腔内注射康柏西普在增生性糖尿病视网膜病变患者中效果显著,可降低眼压,降低视网膜厚度,调节血清因子,提高视力,同时具有一定安全性,提高生活质量。Objective:To explore the effect of vitrectomy combined with intravitreal injection of Conbercept in the treatment of proliferative diabetic retinopathy.Method:A total of 76 patients with proliferative diabetic retinopathy admitted to the Affiliated Eye Hospital of Nanjing Medical University from October 2022 to October 2023 were retrospectively selected.The patients were divided into control group and observation group,38 cases in each group.The control group was given vitrectomy,and the observation group was given vitrectomy combined with intravitreal injection of Conbercept.The recovery,serum factors,quality of life and safety of the two groups were compared.Result:Three months after operation,the best corrected visual acuity(BCVA),intraocular pressure and macular central retinal thickness(CRT)in observation group were lower than those in control group,the differences were statistically significant(P<0.05).Three months after operation,the levels of vascular endothelial growth factor(VEGF)and placental growth factor(PIGF)in observation group were lower than those in control group,the differences were statistically significant(P<0.05).Three months after operation,the Chinese version of low vision quality of life scale(CLVQOL)score in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).The incidence of complications in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05).Conclusion:Intravitreous injection of Conbercept before vitrectomy has a significant effect in patients with proliferative diabetic retinopathy,which can reduce intraocular pressure,reduce retinal thickness,regulate serum factors,improve vision,and have certain safety and quality of life.

关 键 词：增生性糖尿病视网膜病变 玻璃体切除术 玻璃体腔内注射 康柏西普 视力 眼压 

分 类 号：R47[医药卫生—护理学]